On February 21, 2022 Horizon Therapeutics plc (Nasdaq: HZNP) reported that the Company will present at the following conference in March (Press release, Horizon Therapeutics, FEB 21, 2022, https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-present-cowen-and-company-42nd-annual [SID1234608358]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen and Company 42nd Annual Health Care Conference (Virtual)

Date: Tuesday, March 8, 2022
Presentation time: 11:10 a.m. ET
The presentation will be webcast live and may be accessed by visiting Horizon’s website at View Source A replay of the webcast will be available following the event.

On February 21, 2022 Chimeric Therapeutics Limited (ASX:CHM) (Chimeric or Company) reported to conduct a $18.1 million equity raising via an accelerated 1 for 3.15 non-renounceable entitlement offer of fully paid ordinary shares in Chimeric (New Shares) to raise approximately $18.1 million (before costs of the offer)(Entitlement Offer) (Press release, Chimeric Therapeutics, FEB 21, 2022, View Source [SID1234608344]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The offer price for the Entitlement Offer will be $0.17 per share (Offer Price). The Offer Price represents:

• a 11.8% discount to the theoretical ex-rights price (TERP);2
• a 18.3% discount to the 5-day volume weighted average price (VWAP), and
• a 15.0% discount to the last traded price of Chimeric shares.

Under the Entitlement Offer, eligible shareholders will be able to subscribe for 1 new ordinary share in Chimeric for every 3.15 existing shares (and 1 new option for every New Share issued with an 1 Before costs of the offer 2 The theoretical ex-rights price of $0.193 is calculated using Chimeric’s closing price on 18 February 2022 assuming proceeds from the Entitlement Offer of $18.1 million. TERP is the theoretical price at which shares should trade immediately after the ex-date for the Entitlement Offer assuming 100% take-up of the Entitlement Offer. TERP is a theoretical calculation only and the actual price at which shares trade immediately after the ex-date for the Entitlement Offer will depend on many factors and may not be equal to the TERP. CHIMERIC THERAPEUTICS LIMITED ACN 638 835 828 LEVEL 3, 62 LYGON STREET CARLTON VIC 3053 AUSTRALIA exercise price of $0.255 per new option and exercisable on or before 31 March 20243) held at 7pm (AEDT) on Wednesday, 23 February 2022(Record Date) at the Offer Price (Entitlements).

The Entitlement Offer includes an institutional component (Institutional Entitlement Offer) and a retail component (Retail Entitlement Offer).

The Entitlement Offer has been managed by Bell Potter Securities Limited. Bell Potter will receive fees for its lead manager and other services, to be settled in cash.

The Board intends to use the proceeds of the Entitlement Offer to fund payments under the Company’s licence and sponsored research agreements as well as Phase I clinical trials. Funds will also be applied for ongoing working capital and the costs of the Entitlement Offer.

Institutional Entitlement Offer

Eligible institutional shareholders will be invited to participate in the institutional component of the Institutional Entitlement Offer, which is being conducted today, Monday, 21 February 2022. Eligible institutional shareholders can choose to take up all, part or none of their Entitlement. Institutional Entitlements cannot be traded on ASX or transferred. Institutional Entitlements that eligible institutional shareholders do not take up by the close of the Institutional Entitlement Offer, and institutional Entitlements that would otherwise have been offered to ineligible institutional shareholders, will be offered to new institutional investors and existing institutional shareholders concurrently with the Institutional Entitlement Offer. Chimeric’s shares will remain in a trading halt pending completion of the Institutional Entitlement Offer.

Retail Entitlement Offer Eligible retail shareholders in Australia and New Zealand will be invited to participate in the Retail Entitlement Offer at the same Offer Price and offer ratio as the Institutional Entitlement Offer. The Retail Entitlement Offer will open on 28 February 2022 and close at 5:00pm (Sydney time) on 11 March 2022. Further details about the Retail Entitlement Offer will be set out in the Retail Entitlement Offer prospectus (Prospectus), which Chimeric expects to lodge with ASX and dispatch to eligible retail shareholders on 28 February 2022. The Prospectus will also enclose personalised entitlement and acceptance forms.

The Entitlements are non-renounceable and will not be tradeable on ASX or otherwise transferable. Shareholders who do not take up their Entitlements will not receive any value for those 3 Institutional Shareholders must, at the issuance date of new Options, hold at least the number of New Shares they subscribed for under the Institutional Entitlement Offer. CHIMERIC THERAPEUTICS LIMITED ACN 638 835 828 LEVEL 3, 62 LYGON STREET CARLTON VIC 3053 AUSTRALIA Entitlements that they do not take up. Shareholders who are not eligible to receive Entitlements will not receive any value for the Entitlements they would have received had they been eligible. Approximately 106.5 million new ordinary shares in Chimeric will be issued as part of the Entitlement Offer. Shares issued under the Entitlement Offer will rank equally with existing shares.

Approximately 106.5 million options over ordinary shares in Chimeric will be issued as part of the Entitlement Offer, with full details set out in the Annexure to the Prospectus. The Retail Entitlement Offer will include a top up facility under which eligible retail shareholders who take up their full Entitlement will be invited to apply for additional shares in the Retail Entitlement Offer from a pool of those not taken up by other eligible retail shareholders. There is no guarantee that applicants under this top up facility will receive all or any of the shares they apply for under the facility. Chimeric will notify shareholders as to whether they are eligible to participate in the Retail Entitlement Offer.

Eligible retail shareholders will receive an information booklet including a personalised entitlement and acceptance form which will provide further details of how to participate in the Retail Entitlement Offer. Also, under ASX Listing Rules, Appendix 7A, Chimeric will despatch a letter about the Entitlement Offer to each holder of options to subscribe for Chimeric shares. A presentation on the Entitlement Offer has been lodged with ASX today and is able to be downloaded from ASX’s website, www.asx.com.au.

On February 21, 2022 Prestige BioPharma Limited (950210: KRX), a Singapore-based biopharmaceutical with operations in USA and South Korea, reported that the manufacturing facility for its Herceptin biosimilar, Tuznue, in Prestige Biologics Co., Ltd. (334970: KOSDAQ), has received European Union Good Manufacturing Practices (GMP) certification (Press release, Prestige BioPharma, FEB 21, 2022, View Source [SID1234608359]). EU-GMP certification is one of the highest standards of pharmaceutical production in the world, and it provides pharmaceuticals with the foundation to start selling their products into European markets.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Tuznue, HD201, is a proposed biosimilar to Roche’s Herceptin and can be prescribed for the treatment of HER2 positive breast and metastatic gastric cancer. Tuznue’s equivalence to the originator has been demonstrated in 2 Phase 1 trials conducted in Europe and Australia and a global Phase 3 trial, which has been published in scientific journals and conferences. Tuznue has secured global distribution partnerships in major markets, and is currently under Marketing Authorization Application (MAA) review in EU EMA, Canada and South Korea.

Prestige BioPharma has strong pipeline portfolio comprising biosimilars and first-in-class antibody drugs. Following the frontrunning Tuznue, a biosimilar to Avastin, HD204 (Vasforda) is wrapping up the global Phase 3 clinical trial targeting filing to FDA and EMA this year. PBP1510 (Ulenistamab), first-in-class antibody drug for pancreatic cancer, and PBP1502, a biosimilar to Humira are currently in Phase 1/2a and Phase 1 clinical trial in Europe, respectively.

Lisa S. Park, CEO of Prestige BioPharma, commented: "EU GMP certification of our manufacturing arm in Korea demonstrated our global standard biomanufacturing facility and system that are applied to all of our products. By achieving one of the key requirements for product registration, we are one step closer to global launch of Tuznue that can enhance affordability of trastuzumab to the patients in need."

On February 21, 2022 Mevion Medical Systems reported it has been selected by Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology to equip their new proton therapy center with a MEVION S250i Proton Therapy System in Wuhan, China (Press release, Mevion Medical Systems, FEB 21, 2022, View Source [SID1234608360]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The system at Tongji Hospital will feature Mevion’s industry leading HYPERSCAN Pencil Beam Scanning (PBS) technology, coupled with the industry’s only proton multi-leaf collimator, the Adaptive Aperture. This powerful duo provides faster and more precise targeted dose delivery to tumors thus further minimizing the damage to surrounding healthy tissue and organs at risk. The system also integrates a diagnostic CT imaging system and a surface tracking system for high precision patient positioning and intra-fraction motion management.

Founded in 1900 and listed as the 6th top hospital in Fudan’s 2020 China Hospital Ranking, Tongji Hospital provides over 6 million annual outpatient visits. The contract for the new proton therapy center was completed in late 2021, and construction of the new 135,000 square-foot proton therapy center at Tongji Hospital’s Optics Valley campus is expected to be completed by December 2022. The installation of the MEVION S250i is planned to commence in July.

Tongji Hospital will build a second proton vault simultaneously, making it China’s first proton center applying the One Plus One multi-system installation approach. This allows Tongji Hospital the flexibility to add a second system in the future to correspond to the growth of patient volume and clinical expertise. This staged installation significantly reduces the financial burden at the start of the clinical proton therapy program and minimizes the risk of technology obsolescence.

"Mevion is proud to partner with the distinguished Tongji Hospital to provide accessible proton therapy to their patients," said Tina Yu, Ph.D., chief executive officer and president of Mevion. "Mevion strongly believes health care systems will greatly benefit from expanding their proton centers at their optimal pace with the most advanced technology to best serve their patients."

On February 21, 2022 The Sistema Group company (LSE: SSA, MOEX: AFKS), Binnopharm Group, one of the leading pharmaceutical production companies in Russia via its affiliate Joint Stock Company ‘Alium’, and Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy’s"), an integrated global pharmaceutical company, reported the signing of a deal that will allow Binnopharm Group to acquire anti-bacterial medicines under the Ciprolet and Levolet brands from Dr. Reddy’s in Russia, Uzbekistan and Belarus (Press release, Dr Reddy’s, FEB 21, 2022, View Source [SID1234608345]). The portfolio includes various dosage forms such as tablets, solution for infusions and eye drops.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Rustem Muratov, CEO of the Binnopharm Group said: "The acquisition of Ciprolet and Levolet is an important step to enhance our position in the antibiotics market, one of the key market segments for Binnopharm Group. These strong brands have already had the trust of millions of consumers – according to independent analyst estimation they are leaders in their market segments. They will be a valuable complement to our portfolio of antibacterial products. We are also acquiring rights to these products in Belarus and Uzbekistan in line with our strategic goal to strengthen presence in the international markets."

M.V. Ramana, CEO – Branded Markets (India & Emerging Markets), said: "Our Russia and CIS markets continue to be strong performers for the company. This deal is a step towards divesting brands in non-core areas in order to consolidate and strengthen our play further in our key focus therapy areas of gastro-enterology, pain management, cold and flu, allergy, oncology, neurology, paediatrics and women’s health. This will help us accelerate access to affordable and innovative medicines in the region in these segments in keeping with our purpose of ‘Good Health Can’t Wait’."

During the transition period, Dr. Reddy’s will continue to supply the product to Binnopharm Group to ensure availability in the market.